QLB After Nephrectomy

M

Medical University of Lublin

Status

Completed

Conditions

Chronic Postoperative Pain
Pain, Postoperative

Treatments

Device: PCA
Drug: Sevoflurane
Drug: Oxycodone
Drug: Fentanyl
Drug: Rocuronium
Procedure: QLB
Procedure: GA

Study type

Interventional

Funder types

Other

Identifiers

NCT03529201
KE-0254/328/2017

Details and patient eligibility

About

Oxycodone consumption and postoperative pain intensity in patients undergoing nephrectomy procedures. Of all study participants, 50% will obtain quadratus lumborum block (QLB).

Full description

Patients undergoing nephrectomy procedures will be allocated to one of the study arms. At the end of an operation, still under general anesthesia, 50% patients will obtain QLB with ropivacaine. Ultrasound-guided QLB will be performed on the side of surgery with 0.375% ropivacaine solution (0.2 mL per kg). Every patient will get patient-controlled analgesia pump with oxycodone in the postoperative period. Postoperative pain will be measured with VAS (visual-analogue scale) 2, 4, 8, 12 and 24 hours after the end of the operation. 24 -hours period. At the 1, 3, 6 months patients will be interviewed by phone to assess neuropathic pain. Neuropathic Pain Symptom Inventory (NPSI) will be used.

Enrollment

105 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • obtained consent
  • nephrectomy procedure

Exclusion criteria

  • coagulopathy allergy to local anesthetics depression, antidepressant drugs treatment epilepsy usage of painkiller before surgery addiction to alcohol or recreational drugs

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

105 participants in 2 patient groups

QLB
Experimental group
Description:
At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
Treatment:
Procedure: GA
Procedure: QLB
Drug: Rocuronium
Drug: Fentanyl
Drug: Oxycodone
Drug: Sevoflurane
Device: PCA
Control
Experimental group
Description:
Standard care. No regional blocks.
Treatment:
Procedure: GA
Drug: Rocuronium
Drug: Fentanyl
Drug: Oxycodone
Drug: Sevoflurane
Device: PCA

Trial contacts and locations

2

Loading...

Central trial contact

Michał Borys, M.D., Ph.D.; Mirosław Czuczwar, M.D., Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems